Geron Corporation (GERN) is a biopharmaceutical company engaged in the research and development of therapeutics for hematologic malignancies. Based in Menlo Park, California, Geron was founded in 1990 and has since garnered a reputation for being a pioneering force in the biomedical realm with a primary focus on oncology and degenerative diseases.
The primary foundation of Geron Corporation's work is based on telomerase, a naturally occurring enzyme believed to play a vital role in cell aging and cancer. Geron has significantly contributed to defining the role of telomerase in cancer and has developed proprietary small molecule inhibitors of telomerase, most notably GRN163L (Imetelstat).
Imetelstat, Geron's lead product candidate, has been considered a potential breakthrough in treating myelofibrosis, a type of bone marrow cancer that interferes with the natural production of blood cells. This drug is currently at the stage of late-phase 2 clinical testing for myelodysplastic syndromes (MDS) and myelofibrosis (MF). If successful in these trials, it could be the first approved telomerase inhibitor.
Geron Corporation, throughout its operation, has consistently displayed a strong commitment to research-based innovation in medicine. It holds to stringent ethical standards in its scientific activities and business practices. The company collaborates actively with other industry entities and academic institutions to further the pursuit of novel treatments for unmet medical needs.
Just as with any company involved in drug development, Geron carries a significant amount of risk. The nature of the pharmaceutical industry is such that even companies like Geron, with groundbreaking ideas and years of diligent research, need to navigate potential regulatory hurdles, highly expensive clinical trials, and the complex process of bringing a drug to market. Nonetheless, Geron Corporation shows promise in its field and remains dedicated to altering the course of medicine with its innovative therapies.
Over the course of its history, Geron Corporation has demonstrated a commitment to pushing the boundaries of biomedical science to better understand the role of telomeres in cellular functioning, with an ultimate objective of introducing breakthroughs in the medical field. Despite the massive challenges inherent in drug discovery and development, Geron continues to strive to discover lasting and impactful solutions for individuals suffering from debilitating diseases. The innovative spirit and hardcore perseverance that has defined its journey in the market make Geron a fascinating player in the healthcare sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article provides analyst insights on two NA sector companies: Geron (GERN) and Fair Isaac (FICO). Geron received a Hold rating from H.C. Wainwright analyst Emily Bodnar, with a strong buy consensus and a target upside of 233.1%. Fair Isaac was reiterated as a Buy by Wells Fargo analyst Jason Haas CFA, with a moderate buy consensus and a target upside of 56.3%.
Geron (NASDAQ: GERN) anticipates RYTELO revenue to reach the higher end of its 2026 guidance, targeting approximately $230 million to $240 million, driven by strong community oncology adoption. The company reported record quarterly revenue of $57.5 million and is focusing on expanding RYTELO's use in community settings, where 80% of the lower-risk Myelodysplastic Syndromes (MDS) market resides. Geron also plans to outline its European commercialization strategy by year-end and continues its Phase 3 trial for myelofibrosis, while maintaining over $300 million in cash.
Geron anticipates RYTELO's 2026 revenue to be at the higher end of its $230 million–$240 million guidance, driven by consistent growth, a 24% increase in first-half revenue, and reduced operating expenses. The company is strategically expanding RYTELO's use in community settings and focusing on earlier-line treatment for lower-risk MDS patients, while also exploring partnership options for European markets. Geron maintains strong financial flexibility with over $320 million in cash and is engaged in regulatory discussions regarding its myelofibrosis study.
Edmond DE Rothschild Holding S.A. has acquired a new position in Geron Corporation, purchasing 2,330,000 shares valued at approximately $2,982,000. This makes Edmond DE Rothschild Holding S.A. an owner of about 0.36% of Geron. Other institutional investors like RA Capital Management L.P., BlackRock Inc., and Vanguard Group Inc. have also significantly modified their holdings in the biopharmaceutical company.
Geron (GERN) has shown positive stock performance recently following its Q2 and H1 2026 earnings report and new RYTELO guidance, which provides clearer revenue visibility. The company's valuation narrative suggests it is 53.2% undervalued, with a fair value of $3.40 per share, driven by aggressive revenue expansion and pipeline catalysts like myelofibrosis expansion and EU approvals. However, the valuation heavily depends on RYTELO's execution and the telomerase pipeline, making it susceptible to setbacks.